Evaluation and Comparison of SAC in the Progression of Multiple Myeloma

Evaluation and Comparison of SAC in the Progression of Multiple Myeloma

Collaborators: University of Arkansas for Medical Sciences (UAMS)

Objective: Evaluation and Comparison of Multiple Myeloma progression by inducing 5TGM1 with Luc cells in NSG mice by the treatment of intraperitoneal injections of SAC

Trial Programs: TAT/PBS Group IVIS
SAC Trial DEXA Analysis

Many people neglect the importance of their bone health. However, in our bodies, bone health is crucial. BMD is even more so in Multiple Myeloma (MM) patients. This is because the bone marrow plays an essential role in making blood. Bone health is directly related to bone marrow production. If you have MM, your BMD will drop rapidly.

Multiple myeloma (MM) is the second most common hematological malignancy. It mainly occurs at older ages and remains an incurable disease. MM is a B cell cancer mainly characterized by the proliferation of malignant plasma cells in the bone marrow, the presence of monoclonal serum immunoglobulin, and the occurrence of osteolytic lesions. MM is highly associated with bone destruction. Osteoclasts (OCS) were shown to enhance bone destruction and support myeloma progression, while osteoblasts (OBs) were shown to enhance bone formation and inhibit myeloma growth.

In MM, the activities of OCS were up-regulated while the OB activity was down-regulated. This evidence suggested that manipulating activities of OCS and/or OBs can be a good candidate for a novel myeloma therapy.

The Multiple Myeloma research team in the University of Arkansas for Medical Sciences (UAMS) Cancer Center has been conducting clinical trials for the effect of SAC on mouse Multiple Myeloma since May 2019, and in January 2022, the result was fruitful that it confirmed that the life span of mice with Multiple Myeloma could be extended from 50 days to 62 days via SAC IV. If we compare this to human life expectancy, we expect to extend the lifespan of humans by 20% or more. In addition, we saw a significant increase in bone density in the additional 8-week clinical trial confirming a 5% increase in BMD. Here we can learn that there is a correlation between good bone health and lifespan.

Back to blog